|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Oral contraceptives and venous thromboembolic disease: the findings from |
| database studies in the United Kingdom and Germany. |
| AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 1998 Sep;179(3 Pt |
| Research articles published in 1995-96 suggested that oral contraceptives (OCs) containing desogestrel or |
| gestodene are associated with an increased risk of venous thromboembolism. This paper presents the findings of |
| two more recent studies on this association, one from the UK and the other from Germany, both of which were based |
| on general practice computer-generated clinical databases. The median age of OC users was 26 years in the UK |
| study and 27 years in the German study. The crude incidence of venous thromboembolism per 10,000 woman-years |
| of OC exposure was 4.1 cases in the UK study and 4.2 cases in Germany. In Germany, this rate was higher among |
| users of second-generation OCs (4.03 cases per 10,000 woman-years) than third-generation OCs (3.95 cases per |
| 10,000 woman-years). In the UK, the reverse pattern was found: 4.96 and 3.10 cases per 10,000 woman-years for |
| third- and second-generation products, respectively. Moreover, crude incidence rates were higher for the 20 mcg |
| estrogen-desogestrel formulation than for the OC containing desogestrel and 30 mcg of estrogen--a biologically |
| implausible finding. The adjusted odds ratios in the UK study did not show any significant increases in venous |
| thromboembolism risk for desogestrel or gestodene compared with levonorgestrel. Overall, these findings fail to |
| provide support for the hypothesis that the newer progestogens are more likely to cause venous thromboembolism. |
| (PubHealth.info Document ID: CONT2T 10-06) |
| PubHealth.info NOTE: The author(s) of this article titled, "Oral contraceptives and venous thromboembolic disease: |
| the findings from database studies in the United Kingdom and Germany.", is(are) Farmer RD; Lawrenson RA. The |
| source of this article is "AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 1998 Sep;179(3 Pt 2):S78- |
| 86.". This article was published in 1998 in English language(s). (PubHealth.info® Document ID: CONT2T 10-06. All |
| rights reserved with PubHealth.info) PIN: 5010 |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |